Aktienanalyse zu Inhibikase Therapeutics Inc (IKT)

KI-Analyse of Inhibikase Therapeutics Inc (IKT)

Halten

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Inhibikase Therapeutics Inc (IKT) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -2.42.

Erwartetes KGV

Überbewertet

5J-Durchschnitt P/E

-2.42

Aktuelles P/E

0.00

Überbewertet

-0.53

Unterbewertet

-4.32

Erwartetes EV/EBITDA

Stark unterbewertet

5J-Durchschnitt EV/EBITDA

0.00

Aktuelles EV/EBITDA

0.00

Überbewertet

0.00

Unterbewertet

0.00

Erwartetes KUV

Stark überbewertet

5J-Durchschnitt P/S

150.84

Aktuelles P/S

826.05

Überbewertet

463.07

Unterbewertet

-161.39

Alphio-AI-Kursszenarien für IKT

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%IKT

$2.41

Szenariopreis

B

Basis

Basis · 50%IKT

$2.22

Szenariopreis

B

Bärisch

Bärisch · 25%IKT

$2.07

Szenariopreis

Whales, die IKT halten

B

Blackstone Alternative Investment Advisors LLC

+ HältIKT

-0.88%

3-Monats-Rendite

S

Soleus Capital Management, L.P.

+ HältIKT

-7.34%

3-Monats-Rendite

A

ADAR1 Capital Management, LLC

+ HältIKT

-14.25%

3-Monats-Rendite

IKT FAQ – beantwortet von Alphio AI

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.